ABTAbbott LaboratoriesQ2 2026Earnings Analysis

Exact Sciences Acquisition Reshapes Diagnostics Segment

Abbott completed the $20.6 billion acquisition of Exact Sciences on March 23, 2026, funded primarily through $20.0 billion in newly issued long-term debt. Exact Sciences' results are now reported as 'Cancer Diagnostics' within the Diagnostic Products segment, contributing approximately $1.0 billion in net sales for the first six months of 2026, and driving Diagnostic Products segment growth of 42.3% in Q2 2026 (41.3% excluding FX).

Source: 10-Q Item 2 MD&A

Segment Performance Diverges

For the six months ended June 30, 2026, Medical Devices grew 8.0% excluding FX (led by double-digit growth in Electrophysiology +13.0%, Rhythm Management +10.9%, and Heart Failure +10.4%), and Established Pharmaceutical Products grew 8.9% excluding FX. In contrast, Nutritional Products declined 5.6% excluding FX due to lower volumes in adult and U.S. pediatric nutritionals.

Source: 10-Q Item 2 MD&A

Diabetes Care and CGM Momentum Continues

Diabetes Care sales increased 8.2% excluding FX in the first six months of 2026, driven by continuous glucose monitoring (CGM) systems, which totaled $4.1 billion versus $3.6 billion in the prior-year period, an 8.6% increase excluding FX. In May 2026, Abbott also secured a CE Mark for Libre Duo, its dual glucose-ketone biowearable sensor.

Source: 10-Q Item 2 MD&A

Margin Pressure from Acquisition Costs

Gross profit margin was 52.5% in Q2 2026 and the first six months, down from 52.7% in the prior-year periods, primarily due to higher intangible amortization from the Exact Sciences acquisition. SG&A expenses rose 30.3% to $4.0 billion in Q2 2026, driven by Exact Sciences integration expenses, higher legal reserves, and increased selling/marketing spend, while R&D rose 22.9% to $892 million.</br>

Source: 10-Q Item 2 MD&A

Liquidity Impacted by Acquisition Financing

Cash and cash equivalents decreased from $8.5 billion at December 31, 2025 to $5.1 billion at June 30, 2026, primarily due to funding the Exact Sciences acquisition and repaying $2.8 billion of assumed debt. Working capital declined from $9.5 billion to $6.7 billion over the same period, while operating cash flow for the first six months of 2026 increased $339 million YoY to $3.8 billion.

Source: 10-Q Item 2 MD&A

Abbott has received multiple Statutory Notices of Deficiency (SNODs) from the IRS totaling over $1 billion in proposed adjustments for the 2017-2020 tax years, primarily related to income reallocation between U.S. entities and foreign affiliates. Abbott has filed petitions with the U.S. Tax Court contesting these assessments and believes the adjustments are without merit, but litigation outcomes remain uncertain.

Source: 10-Q Item 2 MD&A

Abbott received a $413 million tax assessment from Malaysian tax authorities in July 2024 related to capital gains tax on an intercompany share sale, which was upheld by the Penang High Court in October 2025. Abbott has filed an appeal with the Malaysian Court of Appeals, but an adverse final outcome could result in a material cash tax liability.

Source: 10-Q Item 2 MD&A

The $20.6 billion Exact Sciences acquisition was funded primarily with $20.0 billion of newly issued long-term debt, significantly increasing interest expense (up $268 million to $367 million in the first six months of 2026) and reducing cash reserves from $8.5 billion to $5.1 billion. Integration costs, higher legal reserves, and elevated SG&A/R&D spending tied to the acquisition could pressure near-term profitability if synergies are not realized as planned.

Source: 10-Q Item 2 MD&A

Nutritional Products sales declined 5.6% excluding FX in the first six months of 2026, driven by lower volumes across U.S. pediatric (-11.9%) and adult nutritionals; Rapid and Molecular Diagnostics also declined 8.8% excluding FX due to weaker respiratory virus testing demand. Continued softness in these segments could offset growth from newer acquisitions and higher-growth franchises.

Source: 10-Q Item 2 MD&A